INVO FERTILITY INCORPORATED (IVF)

Revenue grew 5% year-over-year to $6.84 million, with net loss from continuing operations narrowing to $(5.3) million. The company expanded to four clinics, strengthened its balance sheet with $11.5 million in new financing, and continues to pursue organic and acquisition-driven growth.Original ...

Revenue grew 5% to $6.8M in 2025, driven by clinic operations, but net loss from continuing operations was $5.3M. The company completed a key clinic acquisition, settled major litigation, and remains focused on expanding its fertility platform amid ongoing liquidity and regulatory risks.Original ...

Nasdaq flags INVO for missing its 2025 10-K and Q1 10-Q; 10-K is now filed and the firm has until June 22 to submit a compliance plan.

INVO Fertility (NASDAQ:IVF – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported $472.78 earnings per share for the quarter, FiscalAI reports. The firm had revenue of $1.60 million for the quarter. INVO Fertility Price Performance INVO Fertility stock opened ...

IVF fell 21.81% while key peers showed mixed moves: VERO up 0.98%, TIVC up 7.69%, NAOV down 1.95%, NUWE down 4.1%, RMED flat. This points to stock-specific pressure rather than a sector-wide move. ... Earnings releases have generally featured revenue growth but ongoing losses, with share-price ...